You just read:

Final Results of NAPOLI-1 Study Confirm Overall Survival and Progression-Free Survival Benefit for the ONIVYDE® Regimen for Patients with Metastatic Pancreatic Cancer

News provided by

Merrimack Pharmaceuticals, Inc.

Oct 11, 2016, 07:30 ET